Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment-Resistant Depression: New Therapies on the Horizon

Treatment-Resistant Depression: New Therapies on the Horizon Managing patients with treatment-resistant depression (TRD) remains a major challenge for the practicing physician. Depression is considered treatment-resistant when at least two adequate monotherapy trials with drugs from different pharmacologic classes fail to elicit a therapeutic response. Although determining the stage of TRD may allow concise description of a patient's antidepressant history, management of TRD is better served by recent attempts to create a treatment algorithm that encompasses definitive diagnosis of true TRD and strategies for optimizing available therapies, including consideration of novel treatment options. Present strategies for managing TRD include optimization of the initial drug, substitution of another drug from the same or a different antidepressant class, combination of two antidepressants with different mechanisms of action, and adding an antidepressant drug from another class. Potential nonpharmacologic treatments include vagus nerve stimulation, repetitive transcranial magnetic stimulation, and magnetic seizure therapy as an alternative to electroconvulsive therapy. Several neuropeptides and their receptors have also been identified as potential targets for pharmacologic intervention, including corticotropin-releasing factor and substance P. Other treatments currently under investigation include augmentation of antidepressant therapy with an atypical antipsychotic agent such as olanzapine or risperidone. This kind of therapeutic intervention may prove to be especially useful in treating patients with TRD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Treatment-Resistant Depression: New Therapies on the Horizon

Trivedi, Madhukar
Annals of Clinical Psychiatry , Volume 15 (1) – Oct 11, 2004
Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/treatment-resistant-depression-new-therapies-on-the-horizon-oXWwswCzwh
Publisher
Springer Journals
Copyright
Copyright © 2003 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1023232727217
Publisher site
See Article on Publisher Site

Abstract

Managing patients with treatment-resistant depression (TRD) remains a major challenge for the practicing physician. Depression is considered treatment-resistant when at least two adequate monotherapy trials with drugs from different pharmacologic classes fail to elicit a therapeutic response. Although determining the stage of TRD may allow concise description of a patient's antidepressant history, management of TRD is better served by recent attempts to create a treatment algorithm that encompasses definitive diagnosis of true TRD and strategies for optimizing available therapies, including consideration of novel treatment options. Present strategies for managing TRD include optimization of the initial drug, substitution of another drug from the same or a different antidepressant class, combination of two antidepressants with different mechanisms of action, and adding an antidepressant drug from another class. Potential nonpharmacologic treatments include vagus nerve stimulation, repetitive transcranial magnetic stimulation, and magnetic seizure therapy as an alternative to electroconvulsive therapy. Several neuropeptides and their receptors have also been identified as potential targets for pharmacologic intervention, including corticotropin-releasing factor and substance P. Other treatments currently under investigation include augmentation of antidepressant therapy with an atypical antipsychotic agent such as olanzapine or risperidone. This kind of therapeutic intervention may prove to be especially useful in treating patients with TRD.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 11, 2004

References

  • The functioning and well-being of depressed patients: Results from the Medical Outcomes Study
    Wells, KB; Stewart, A; Hays, RD; Burnam, MA; Rogers, W; Daniels, M; Berry, S; Greenfield, S; Ware, J
  • Assessment and treatment of suicidal patients
    Hirschfeld, RM; Russell, JM
  • Depression in primary care: Guideline overview
  • What next? A review of pharmacologic strategies for treatment resistant depression
    Nierenberg, AA; White, K
  • Treating Resistant Depression: II
    Thase, ME; Kupfer, DJ
  • Definition and epidemiology of treatment-resistant depression
    Fava, M; Davidson, KG
  • When at first you don't succeed: Sequential strategies for antidepressant responders
    Thase, ME; Rush, AJ
  • Treating depression to remission
    Rush, AJ; Trivedi, MH
  • Psychopharmacology: The Fourth Generation of Progress
    Thase, ME; Rush, AJ
  • Treating antidepressant nonresponders with augmentation strategies: An overview
    Thase, ME; Howland, RH; Friedman, ES
  • Using treatment algorithms for the effective management of treatment-resistant depression
    Trivedi, MH; Kleiber, BA
  • Which depressed patients respond to nefazodone and when?
    Trivedi, MH; Rush, AJ; Pan, JY; Carmody, TJ
  • CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders VII: comorbidity
    Enns, MW; Swenson, JR; McIntyre, RS; Swinson, RP; Kennedy, SH
  • The management of treatment-resistant depression in the medically ill
    Franco-Bronson, K
  • Practical management of treatment-resistant depression
    Cadieux, RJ
  • Time to recovery, chronicity and levels of psychopathology in major depression: A five-year prospective follow-up of 431 subjects. Major depressive disorder
    Keller, MB; Lavori, PW; Mueller, TI; Endicott, J; Coryell, W; Hirschfeld, RM; Shea, T
  • Three-year outcomes for maintenance therapies in recurrent depression
    Frank, E; Kupfer, DJ; Perel, JM; Cornes, C; Jarrett, DB; Mallinger, AG; Thase, ME; McEachran, AB; Grochocinski, VJ
  • Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatment
    Byrne, SE; Rothschild, AJ
  • Clinical issues in long-term treatment with antidepressants
    Zajecka, JM
  • Overcoming treatment resistance in depression
    Nelson, JC
  • Management of nonresponse and intolerance: Switching strategies
    Fava, M
  • Are patients who are intolerant to one SSRI intolerant to another?
    Brown, W; Harrison, W
  • Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another?
    Brown, WA; Harrison, W
  • Response to an open trial of a second SSRI in major depression
    Joffe, RT; Levitt, AJ; Sokolov, ST; Young, LT
  • Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
    Thase, ME; Blomgren, SL; Birkett, MA; Apter, JT; Tepner, RG
  • Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors
    Nurnberg, HG; Thompson, PM; Hensley, PL
  • Partial response, non-response, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current “next-step” practices
    Fredman, SJ; Fava, M; Kienke, AS
  • Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression
    Thase, ME; Rush, AJ; Howland, RH; Kornstein, SG; Kocsis, JH; Gelenberg, AJ; Schatzberg, AF; Koran, LM; Keller, MB; Russell, JM; Hirschfeld, RM; LaVange, LM; Klein, DN; Fawcett, J; Harrison, W
  • Venlafaxine and treatment-resistant depression
    Thase, ME; Friedman, ES; Howland, RH
  • Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial
    Fava, M; Dunner, DL; Greist, JH; Preskorn, SH; Trivedi, MH; Zajecka, J; Cohen, M
  • Augmentation strategies in depression 2000
    Nelson, JC
  • From scientific knowledge to the clinical practice of psychopharmacology: can the gap be bridged?
    Rush, AJ; Prien, RF
  • Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review
    Zajecka, J; Tracy, KA; Mitchell, S
  • Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression
    Rothschild, AJ; Samson, JA; Bessette, MP; Carter-Campbell, JT
  • Pharmacotherapy of delusional depression: Experience with combination of antidepressants with zotepine and haloperidol as neuroleptics
    Wolfersdorf, M; Konig, F; Straub, R
  • Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
    Tran, PV; Dellva, MA; Tollefson, GD; Beasley, CM; Potvin, JH; Kiesler, GM
  • Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haldol
    Tollefson, GD; Beasley, CM; Tamura, RN; Tran, PV; Potvin, JH
  • Risperidone: Clinical safety and efficacy in schizophrenia
    Borison, RL; Pathiraja, AP; Diamond, BI; Meibach, RC
  • Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate, and dorsal raphe nucleus
    Lukoski, JM; Aghajanian, GK
  • Risperidone augmentation of SSRIs in major depression
    Ostroff, R; Nelson, JC
  • The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors
    Zhang, W; Bymaster, FP
  • Radioreceptor binding profile of the atypical antipsychotic olanzapine
    Bymaster, FP; Calligaro, DO; Falcone, JF; Marsh, RD; Moore, NA; Tye, NC; Seeman, P; Wong, DT
  • Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
    Tollefson, GD; Sanger, TM; Lu, Y; Thieme, ME
  • A novel augmentation strategy for treating resistant major depression
    Shelton, RC; Tollefson, GD; Tohen, M; Stahl, S; Gannon, KS; Jacobs, TG; Buras, WR; Bymaster, FP; Zhang, W; Spencer, KA; Feldman, PD; Meltzer, HY
  • Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
    Zhang, W; Perry, KW; Wong, DT; Potts, BD; Bao, J; Tollefson, GD; Bymaster, FP
  • Depression as a spreading adjustment disorder of monoaminergic neurons: A case for primary implication of the locus coeruleus
    Harro, J; Oreland, L
  • Current trends in the development of new antidepressants
    Pacher, P; Kohegyi, E; Kecskemeti, V; Furst, S
  • Mouse anxiety: The power of knockout
    Lesch, K. P.
  • Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function
    Steinberg, R; Alonso, R; Griebel, G; Bert, L; Jung, M; Oury-Donat, F; Poncelet, M; Gueudet, C; Desvignes, C; Le, F. G.; Soubrie, P
  • Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission
    Haddjeri, N; Blier, P
  • Vagus nerve stimulation therapy for partial-onset seizures
    Handforth, A; DeGiorgio, CM; Schachter, SC; Uthman, BM; Naritoku, DK; Tecoma, ES; Henry, TR; Collins, SD; Vaughn, BV; Gilmartin, RC; Labar, DR; Morris, GL; Salinsky, MC; Osorio, I; Ristanovic, RK; Labiner, DM; Jones, JC; Murphy, JV; Ney, GC; Wheless, JW
  • A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures
  • Vagus nerve stimulation: A new tool for brain research and therapy
    George, MS; Sackeim, HA; Rush, AJ; Marangell, LB; Nahas, Z; Husain, MM; Lisanby, S; Burt, T; Goldman, J; Ballenger, JC
  • Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study
    Rush, AJ; George, MS; Sackeim, HA
  • Vagus nerve stimulation for treatment-resistant depression
    Rosenbaum, JF; Heninger, G
  • Therapeutic application of repetitive transcranial magnetic stimulation: A review
    Wassermann, EM; Lisanby, SH
  • Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: Comparative study of fast, slow, and sham rTMS
    Padberg, F; Zwanzger, P; Thoma, H; Kathmann, N; Haag, C; Greenberg, BD; Hampel, H; Moller, HJ
  • Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression
    Loo, C; Mitchell, P; Sachdev, P; McDarmont, B; Parker, G; Gandevia, S
  • A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression
    Berman, RM; Narasimhan, M; Sanacora, G; Miano, AP; Hoffman, RE; Hu, XS; Charney, DS; Boutros, NN
  • Deliberate seizure induction with repetitive transcranial magnetic stimulation
    Lisanby, SH; Luber, B; Finck, AD; Schroeder, C; Sackeim, HA
  • Magnetic seizure induction for the treatment of major depression [letter]
    Lisanby, SH; Schlaepfer, TE; Fisch, HU; Sackeim, HA
  • Magnetic seizure therapy (MST): Acute cognitive effects of MST compared with ECT
    Lisanby, SH; Luber, B; Barroilhet, L; Neufeld, E; Schlaepfer, T; Sackeim, HA
  • The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder
    Crismon, ML; Trivedi, M; Pigott, TA; Rush, AJ; Hirschfeld, RM; Kahn, DA; DeBattista, C; Nelson, JC; Nierenberg, AA; Sackeim, HA; Thase, ME